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purpose: 18F-fluorodeoxyglucose positron emission tomography combined with 
computed tomography (FDG-PET/CT) is a promising new tool for the identification of 
inflammatory, infectious, and neoplastic foci. The aim of our work was to evaluate the 
diagnostic value of FDG-PET/CT in patients treated on a neurological/neurosurgical ICU 
or stroke unit.
Methods: We performed a single-center, 10-year, retrospective evaluation of the value 
of FDG-PET/CT in critically ill adult patients with severe neurological disease.
Results: 42 patients underwent FDG-PET/CT. Of these, 15 were ventilated and 10 were 
under vasopressor support. We identified four indications for performing FDG-PET/
CT: (1) excluding a paraneoplastic etiology in an otherwise unexplained encephalitis, 
encephalopathy or neuropathy, (2) detecting a large-vessel vasculitis in patients with 
ischemic stroke, (3) detecting an infectious focus in sepsis, and less frequently (4) eval-
uating cerebral metabolism. In 22 patients who were evaluated for an unknown malig-
nancy, 5 scans revealed either a previously unknown tumor or unknown metastases of 
a previously treated malignancy. Of 11 patients investigated for large-vessel vasculitis, 2 
showed an inflammation of arteries supplying the brain. Of six sepsis cases, FDG-PET/
CT identified an infectious focus in four.
Summary: We found FDG-PET/CT to be a helpful tool in critically ill neurological 
patients. The results of the FDG-PET/CT had direct therapeutic consequences in the 
12 true-positive cases. In 24 of the 29 negative cases, FDG-PET/CT helped exclude 
alternative diagnoses and/or influenced therapy. Our findings demonstrate the feasibility 
and diagnostic benefit of FDG-PET/CT in this group of patients.
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InTRoDUcTIon
In recent years, 18F-fluorodeoxyglucose positron emission tomog-
raphy (FDG-PET) has become a recognized and well-researched 
imaging modality for the evaluation of neoplastic, inflammatory, 
and infectious disorders (1). Increased FDG uptake indicates 
increased intracellular glucose metabolism. FDG may accumu-
late in malignant cells as well as in cells involved in inflammatory 
and infectious processes, such as macrophages. Recently, PET 
technology has been combined with computed tomography (CT) 
scanning in a single device. Hybrid imaging by FDG-PET/CT 
offers considerable advantages over regular CT by providing ana-
tomical information in addition to detecting areas with increased 
metabolism. Several studies have documented the important role 
of FDG-PET/CT in detecting unknown malignancies (2), detect-
ing large-vessel vasculitis, (3) and diagnosing patients with fever 
of unknown origin (4).
To our knowledge, there are no previously published reports 
specifically on the use of FDG-PET/CT to identify underlying 
pathologies in critically ill neurological patients. Furthermore, 
data on the use of FDG-PET/CT in critically ill patients are 
scarce, and it has only been used in cases of sepsis or septic 
shock (5, 6). The aim of our 10-year, retrospective analysis was to 
discover which questions were addressed by FDG-PET/CT in our 
set of critically ill, neurological patients and to determine whether 
FDG-PET/CT had been helpful in identifying the relevant under-
lying pathology.
MATeRIAlS AnD MeThoDS
Study Design
This retrospective, observational study included all critically ill, 
adult patients treated on the neurological ICU, neurosurgical 
ICU or stroke unit at the University Medical Center Hamburg-
Eppendorf from March 2006 to May 2015 who had undergone 
FDG-PET/CT for any reason. The study complied with the 
requirements of the local Clinical Institutional Review Board and 
was performed in accordance with the Declaration of Helsinki.
We extracted the following information from the hospital’s 
record system (Integrated Care Manager, Dräger Medical, 
Germany and Soarian Clinicals, Cerner, USA, Inc.): demograph-
ics, diagnosis on admission, diagnosis on discharge (from ICU/
hospital), duration of stay in ICU/hospital, diagnostic procedures 
and treatment prior to FDG-PET/CT, transport-related compli-
cations, clinical course and changes in clinical management after 
having results from FDG-PET/CT, and survival. FDG-PET/CT 
was requested by the attending intensivists at their discretion 
when they considered clinical signs and/or laboratory and/or 
imaging findings to be inconclusive.
18F-Fluorodeoxyglucose positron emission 
Tomography combined with computed 
Tomography
All patients were fasted for at least 4  h before scanning; par-
enteral nutrition and infusions containing glucose were also 
discontinued during that period. Blood glucose concentration 
was checked every hour prior to the administration of 350 MBq 
of 18 F-FDG, which was only performed at glucose levels below 
200 mg/dl. All patients were fully monitored during transport 
and the procedure and were accompanied by a qualified 
intensive care physician and a registered nurse. FDG-PET/
CT was performed with a hybrid PET/CT scanner (Gemini 
GXL10, Philips, Best, Netherlands). The CT part of the exami-
nation included the use of intravenous contrast medium. All 
patients without elevated levels of serum creatinine received 
100–200  ml intravenous contrast agent (Imeron 300, Bracco 
Imaging Konstanz, Germany) 90 s before starting the CT scan. 
The scan took between 30 and 45  min, including positioning 
the patient. Whole-body images were acquired from head to 
leg. All PET scans were performed in 3-dimensional acquisition 
mode. Emission images were acquired for 1.5 min per position 
at head, thorax, and abdomen and 60  s at the legs (effective 
axial field of view: 90 cm). The acquisition parameters were as 
follows: 120 kV, 150 mA, slice thickness 5 mm, no gap, pitch 0.9, 
rotation time 0.74 sec, matrix 512 × 512. CT data extrapolated 
to 511 keV were used for low noise attenuation correction of 
PET data and for subsequent co-registration with attenuation-
corrected PET images. PET, CT, and fused FDG-PET/CT images 
were provided for review and displayed in axial, coronal, and 
sagittal planes. The PET data were available as uncorrected and 
attenuation-corrected images and also as a rotating maximum-
intensity projection.
Interpretation and Analysis of contrast-
enhanced FDg-peT/cT Images
An interdisciplinary team, including one board certified radiolo-
gist and one board certified nuclear medicine physician, who had 
knowledge of the patient’s clinical history, evaluated all scans. 
Initially, PET and CT images were read independently: PET 
images were evaluated by two specialists in nuclear medicine 
(one of them a senior consultant in nuclear medicine) and CT 
images were evaluated by two physicians from the Department 
of Radiology (one of them a senior consultant). Afterward, the 
results of both parts of the investigation were reviewed in a con-
sensus conference of all four physicians resulting in a final written 
report for each FDG-PET/CT investigation.
A focus of increased FDG uptake was considered abnormal 
if it was elevated above the regional background in localiza-
tions outside the expected physiological FDG-distribution. The 
definite clinical diagnosis, which served as the reference standard, 
was made retrospectively taking all available clinical information 
into consideration. These sources of information included clini-
cal course, physical examination, laboratory, microbiology and 
histology results as well as intraoperative findings, electrophysi-
ological examinations, and imaging results other than the FDG-
PET/CT. The FDG-PET/CT results were then compared with the 
final clinical diagnosis and interpreted as true positive (TP) or 
false positive (FP) and true negative (TN) or false negative (FN).
The FDG-PET/CT scan was considered:
• TP—if FDG-PET/CT results demonstrating a localized disease 
process were confirmed by further investigations as the cause 
of the disorder under investigation;
TABle 1 | Demographics, mortality rates, admission diagnosis.
No. of patients 42
Mean age of ALL patients 56.1 ± 15.5 years
With suspected malignancy 55.4 ± 15.0 years
With suspected vasculitis 48.8 ± 11.0 years
With suspected infectious focus 71.3 ± 10.4 years
Mean time in ICU 23.6 ± 16.9 days
Median interval between ICU admission and PET/CT 13 days (range 1–43)
Patients ventilated at time of scan 15 (35.7%)
Patients on vasopressor support at time of scan 10 (23.8%)
Mortality rate 1 (2.4%)
Admission diagnosis
Ischemic stroke 10 (23.8%)
Subarachnoid hemorrhage 3 (7.1%)
Encephalitis/meningitis 8 (19.0%)
Encephalopathy 5 (11.9%)
Seizures 5 (11.9%)
Neuropathy 6 (14.3%)
Infection of unknown origin 5 (11.9%)
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• FP—if FDG-PET/CT results demonstrating a localized disease 
process could not be confirmed as being the cause of the 
disorder under investigation;
• TN—if FDG-PET/CT produced a normal scan and both 
clinical follow-up, and further investigations excluded the 
suspected diagnosis for the disorder under investigation;
• FN—if FDG-PET/CT produced a normal scan, but the 
suspected diagnosis was confirmed by other diagnostic 
procedures.
We also determined whether the FDG-PET/CT results were 
helpful to the clinician, e.g., were essential for making a diagnosis 
or excluding a diagnosis and thus had therapeutic consequences. 
Depending on the question addressed, TP scans and TN scans 
could be considered to be “helpful.”
Reference values concerning the established sensitivity and 
specificity of FDG-PET/CT have been published for detecting 
an underlying malignancy in patients with clinically suspected 
neurological paraneoplastic syndromes (PNSs) (7), detecting 
cerebral metastases (8, 9), detecting a large-vessel vasculitis (10), 
and detecting the etiology of fever of unknown origin (11), as 
well as for determining characteristic spatial patterns of brain 
metabolism in various subtypes of dementia (12).
Statistical Analysis
Continuous variables are provided as means (±SD) for normally 
distributed data, or as medians (with the range) for non-normally 
distributed data. They were calculated using Excel (Microsoft, 
USA).
ReSUlTS
patient characteristics
During the study period, 42 FDG-PET/CT scans were performed 
on critically ill adult patients: 26 were referred from the neurologi-
cal ICU, three from the neurosurgical ICU, and 13 from the stroke 
unit. Demographics, mortality rates, and admission diagnoses of 
the study population are shown in Table 1.
No complications occurred during transportation to or from 
the ICU and the Department of Nuclear Medicine. Adverse reac-
tions to the tracer or the intravenous contrast agents were not 
observed, and the investigation procedure was well tolerated by 
all patients. Hospital survival rate was 97.6% (41 of 42 patients).
We found four indications for performing an FDG-PET/
CT in these patients: (1) excluding a malignancy as the cause of 
neurological symptoms, (2) detecting a large-vessel vasculitis of 
arteries serving the brain, (3) detecting a septic focus, and less 
frequently (4) evaluating cerebral metabolism.
Diagnostic Value of FDg-peT/cT Results
All diagnostic tests performed before FDG-PET/CT, the final 
diagnosis, and correlation with FDG-PET/CT findings (42 
scans) are shown in Tables A–C in Supplementary Material. 
Pathological FDG accumulations were found in 13 of 42 (31%) 
of PET/CT scans, of which 12 (29%) were TPs. These TPs were 
observed most frequently in the group of patients with suspected 
unknown infectious focus followed by the group with suspected 
malignancy and finally in those with suspected vasculitis (67, 
23, and 18%, respectively). Negative results were obtained in 29 
cases (69% of FDG-PET/CT scans). None of these findings were 
considered FNs. This represents an overall accuracy of 97.6%. 
Table  2 shows the distribution of TPs (12), FPs (1), TNs (29), 
and FNs (0) in relation to the suspected diagnosis (i.e., suspected 
malignancy, suspected vasculitis, suspected infectious focus, or 
altered cerebral metabolism).
We also recorded whether the clinician deemed the FDG-PET/
CT “helpful.” This was usually the case when the scan was essential 
for making a diagnosis or had therapeutic consequences. In this 
context, all TP results were considered helpful. However, depend-
ing on the question addressed, TN scans could also be “helpful,” 
and this was the case in 24 of the 29 negative investigations in 
which the PET/CT result helped exclude alternative diagnoses 
and/or influenced therapy. Negative results were especially help-
ful when excluding a malignancy or a large-vessel vasculitis as 
the cause of neurological symptoms and rather unhelpful when 
searching for infectious foci in persisting sepsis. Overall, PET/CT 
was considered helpful in 86% of cases.
patients with Suspected Malignancy
The single most important reason for performing an FDG-PET/
CT scan was detecting a suspected malignancy. This was the rea-
son for 22 (52%) of the scans. In 12 of these patients, the clinician 
suspected a paraneoplastic encephalitis or encephalopathy, in 6 
a paraneoplastic neuropathy, in 3 directly a tumor or metastasis, 
and in 1 patient a paraneoplastic coagulopathy (see Figure  1). 
Five scans (22.7%) revealed either a previously unknown tumor 
or metastasis (TP). Detection of a metastasis could indicate the 
recurrence of previously treated malignancy, a novel tumor or 
the presence of a cancer of unknown origin. In four patients, 
FDG-PET/CT was crucial for the detection of the malignancy. In 
the other patient, the PET/CT confirmed a suspected malignancy.
In one case, a suspected malignancy was not confirmed after 
extensive workup (FP). In the 16 negative cases, the FDG-PET/
CT was considered helpful in excluding the differential diagnosis 
of a tumor.
FIgURe 2 | This 38-year-old woman presented with severe 
headaches. MRI revealed a swollen right hemisphere and impaired cerebral 
perfusion. Treatment with steroids was initiated. PET/CT revealed an 
enhancement of the supra-aortic arteries suggestive of a large-vessel 
vasculitis (red arrows). Takayasu arteritis was diagnosed.
FIgURe 1 | This 36-year-old woman had a thrombosis of her left leg due to a coagulopathy and suffered multiple embolic ischemic strokes. Neither 
ultrasound of the carotid arteries, cardiac ultrasound, nor cerebral angiography revealed any causative pathology. (A) PET/CT revealed a diffuse, blotchy 
enhancement of the left lung suggestive of a bronchoalveolar carcinoma (red arrows). Green arrows depict the healthy right lung. The PET/CT overlay is shown on 
the left side, with the conventional PET-scan on the right. (B) Multiple suspicious lymph nodes were identified in the neck. A biopsy revealed an adenocarcinoma.
TABle 2 | Diagnostic value of an FDg-peT/cT scan.
Indication True positive False positive True negative False negative peT-cT considered 
helpful
peT-cT not 
helpful
Detecting a malignancy (22 patients) 5 (23%) 1 (4%) 16 (73%) 0 21 (96%) 1 (4%)
Detecting a vasculitis (11 patients) 2 (18%) 0 9 (82%) 0 8 (73%) 3 (27%)
Detecting a septic focus (6 patients) 4 (67%) 0 2 (33%) 0 4 (67%) 2 (33%)
Evaluating cerebral metabolism (3 patients) 1 (33%) 0 2 (67%) 0 3 (100%) 0
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patients with Suspected large-Vessel 
Vasculitis
The second most important reason for performing an FDG-PET/
CT scan was to demonstrate or exclude a large-vessel vasculitis 
(11 patients, 26% of all cases). Two of the 11 patients (18.2%) 
displayed inflammation of large vessels supplying the brain, 
indicative of a Takayasu vasculitis (TP) (see Figure 2).
In three cases, a negative PET/CT was considered helpful as 
the scan demonstrated no persisting large-vessel vasculitis under 
immunosuppressive therapy (TN after therapy, helpful). In a 
further three cases, the diagnosis of a vasculitis was rejected after 
PET/CT in conjunction with other studies did not demonstrate 
any pathology (TN, helpful).
In the three remaining cases, PET/CT helped exclude a 
large-vessel vasculitis, but based on further workup, a diagnosis 
of a medium/small vessel vasculitis was made. In two of these 
cases, a conventional angiography was decisive. In the third 
case, the clinical course was highly suggestive of a vasculitis. In 
all three patients immunosuppressive therapy was initiated and 
maintained. In these three cases, PET/CT was not helpful in 
determining the underlying pathology (TN, not helpful).
patients with Suspected Infectious Focus
Detecting the inflammatory focus in patients with sepsis, in 
whom the etiology could not be determined otherwise, was a less 
common indication for performing an FDG-PET/CT scan in our 
case series of neurological patients (six subjects, 14% of all cases). 
Nevertheless, when performed, relevant pathological results were 
demonstrated in 66.7% of cases (four of six patients). An example 
in which determining the extent of the infection was helpful is 
shown in Figure 3.
In cases of sepsis, only TP scans were considered “helpful” 
by the clinician. One patient (TP in PET/CT) died as a result of 
septic shock with multiple organ failure due to a spondylodiscitis.
patients with Altered cerebral Metabolism
Altered cerebral metabolism refers to changes in FDG uptake by 
brain tissue itself in contrast to FDG uptake by cells that may 
have invaded the brain such as tumor cells or inflammatory 
cells. Evaluating cerebral metabolism was a relatively rare reason 
for performing an FDG-PET/CT scan in the study population 
(3 subjects, 7% of cases). The first patient displayed rapidly 
progressive cognitive decline, but the PET/CT was normal. No 
evidence for a neoplastic or inflammatory lesion was found. A 
neurodegenerative disease was excluded. The final diagnosis was 
a normal pressure hydrocephalus.
FIgURe 3 | This 57-year-old man presented with fever and shortness of breath. Antibiotic treatment was initiated. Shortly, he developed right sided 
hemiparesis and confusion. Cultures remained sterile. (A) PET/CT revealed multiple cerebral and cerebellar abscesses. (B) Further abscesses were identified 
throughout the body: at the side of the thyroid gland (red arrow), within the lung (green arrows), liver, and both adrenal glands (blue arrows) as well as multiple foci 
within muscles (orange arrows). A nocardiosis was suspected. Nocardia farcinia was eventually cultured from a bronchoalveolar lavage confirming the diagnosis.
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The second patient suffered a cerebellar hemorrhage. 
Thorough clinical and neurophysiological investigations could 
not determine whether the patient was awake and conscious. 
The PET/CT demonstrated a completely normal supratentorial 
activity. A diagnosis of locked-in syndrome was made.
The third patient suffered from intractable focal seizures. The 
FDG-PET/CT demonstrated focally increased brain activity. 
Seizures ceased after neurosurgical extraction of the epileptic 
focus. In all three cases, the PET/CT was considered helpful by 
the clinician.
Additional Findings
Twenty-seven of the 42 scans (64%) revealed additional findings 
of which 3 (11%) had therapeutic consequences. These were a 
thrombosis adjacent to a central venous catheter (the catheter was 
removed), a thrombus in the right jugular vein (anticoagulation 
was increased), a subdural hygroma not present on a previous CT 
scan (the hygroma was surgically drained).
DIScUSSIon
Our findings show that FDG-PET/CT is useful for the diagnostic 
work-up of critically ill neurological patients. The FDG-PET/CT 
scan was considered to be “helpful for diagnosis or treatment” in 
36 of 42 patients (86%) by the treating clinician. Positive (33%) 
as well as negative (67%) findings contributed to this opinion. 
The ratio of positive to negative findings was clearly related to the 
diagnosis under investigation.
The largest group in our sample was patients with suspected 
PNS. Previous research has suggested that the yield of FDG-PET/
CT may be rather low when investigating PNS (13). Bannas et al., 
using combined PET/CT, identified malignancy as the underly-
ing cause of suspected PNS in only 8.7% of cases. In our sample 
of critically ill neurological patients, the yield was higher (22.7%). 
This number is closer to the 19% reported by other investigators 
(14). In our study population, a large proportion had already been 
investigated extensively before the decision was made to perform 
a PET/CT scan. The cost of getting these critically ill patients into 
the scanner may have led to a more rigorous selection, explaining 
the higher yield compared with other studies.
In our series, 22 patients were investigated for an unknown 
malignancy. FDG-PET/CT revealed a previously unknown 
tumor in two cases and a recurrence of a previously treated 
tumor in three further cases. PET/CT has been shown to be 
better at detecting unknown malignancies than other modali-
ties such as contrast-enhanced CT (CECT) (15). Nevertheless, 
in our study, FDG PET-CT was mostly performed as an add-on 
after inconclusive or negative results from regular investiga-
tions attempting to detect a malignancy (e.g., CECT, abdominal 
ultrasound, and search for paraneoplastic antibodies). In two 
cases, PET/CT revealed a tumor despite extensive prior workup 
including CECT. In a further case, CECT had indicated a spinal 
tumor, and PET/CT was performed to provide more detail and 
search for further metastases. In only nine cases, an FDG/CT was 
performed without prior CECT workup. This decision was made 
by the responsible physician. Reasons for this approach were a 
high suspicion of malignancy, avoiding repeat investigations 
in critically ill patients, and reducing the radiation exposure 
from CECT plus PET/CT. In two of these nine cases, in which 
FDG-PET was performed without prior CECT, a malignancy was 
detected (22%).
The cause of PNS was identified as a bronchial carcinoma (two 
cases), a breast carcinoma (two cases), and a prostate carcinoma 
(one case). PNSs are associated most frequently with lung cancer 
(16), but PNS may also occur in other cancers such as breast 
cancer (17) and prostate cancer (18).
We found FDG-PET/CT helpful for detecting or excluding a 
large-vessel vasculitis as well as for monitoring disease activity in 
patients with established large-vessel vasculitis. In the two cases 
with positive findings, the final diagnosis was a Takayasu arteritis 
6Kampe et al. FDG-PET/CT in Neurocritical Care
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(TA). The clinical value of FDG-PET in detecting TA is well estab-
lished (19). In addition, PET/CT may be helpful in monitoring 
the activity of a large-vessel vasculitis after treatment. As previ-
ously described, PET/CT may reliably detect early changes in the 
disease and identify non-responders to therapy (10, 20). In three 
such cases with previously established large-vessel vasculitis, the 
negative PET/CT finding was considered helpful in evaluating 
treatment success by the clinician.
It is important to point out that an inflammation of middle-
sized or small vessels may escape detection in an FDG PET/CT 
scan. Determining the presence of a vasculitis restricted to the 
small arteries of the central nervous system is extremely difficult 
(21). Often a combination of investigations including conven-
tional angiography, MRI, cerebrospinal fluid examination, and 
possibly even histologic confirmation after a biopsy is required 
for the diagnosis of a primary angiitis of the central nervous 
system. In our set of patients, a conventional angiography was 
decisive in two cases in which PET/CT had yielded negative 
results. In addition to technical investigations, a comprehensive 
and systematic review of the clinical course is paramount for the 
final diagnosis of a vasculitis (22). In one of our cases, the clinical 
course led to a decision that a cerebral vasculitis must be present 
despite inconclusive or negative findings in all investigations 
including PET/CT.
Detecting the source of an infection in patients with sepsis was 
a less frequent reason for performing FDG-PET/CT in our set 
of patients. Nevertheless in the six cases, in which investigations 
were requested with this question in mind, they had consider-
able urgency due to the fact that prompt and adequate therapy is 
crucial for survival in sepsis (23). PET/CT was successful in iden-
tifying the source of an infection in a large proportion of cases, 
comparable to the results of Kluge et al. (5) (67% here compared 
to 61% in the previous study). The results often indicated specific 
therapeutic measures or changes in therapy. Interestingly, the 
only recorded fatality occurred in this group. When searching 
for the infectious focus in a patient with persistent sepsis, only TP 
scans were considered helpful by the clinician.
Evaluating cerebral metabolism was a relatively rare indication 
for performing an FDG-PET/CT in our population of critically 
ill neurological patients. One patient was investigated to clarify 
the nature of a rapidly progressing dementia. Brain FDG-PET 
can show characteristic spatial patterns of brain metabolism 
which are helpful in differentiating subtypes of dementia and 
thus may be helpful in making a diagnosis and in initiating 
appropriate management (12). However, FDG-PET/CT did 
not yield a pathological finding specific to a particular type of 
dementia in this case. A second patient underwent PET/CT 
scans to identify an epileptic focus. FDG-PET has been used to 
localize epileptic foci for some time (24). After characterization 
of the epileptic focus, this patient proceeded to surgical treat-
ment. One patient received a PET/CT scan to determine whether 
he had locked-in syndrome or was in a persistent vegetative state 
after a cerebellar hemorrhage. Extensive clinical monitoring had 
yielded inconclusive results. Recent studies have suggested using 
technology-based assessments including PET in this challeng-
ing group of patients with disorders of consciousness (25–27). 
FDG-PET/CT demonstrated a regular supracortical pattern 
in this patient leading to the conclusion that he had locked-in 
syndrome. Although investigating cerebral metabolism with 
FDG-PET/CT is possible in critically ill neurological patients, it 
is a rather rare indication which can usually be postponed until 
the patient is more stable.
In summary, FDG-PET/CT scanning appears to be a valuable 
diagnostic tool in this selected population of critically ill neu-
rological patients when extensive prior diagnostic work-up has 
been negative or inconclusive. Nevertheless, the difficulties in 
performing this diagnostic procedure in such a cohort of patients 
should be mentioned. One of these is that transporting critically 
ill patients from the ICU or stroke unit to the department of 
nuclear medicine puts these patients at risk, especially when 
they require ventilator or vasopressor support (28, 29). However, 
no adverse events related to transportation or the imaging itself 
were observed in our case series. Furthermore, the investigation 
requires substantial resources in terms of both time and personnel 
in addition to being rather expensive (30). These considerations 
need to be weighed against the diagnostic benefit in this popula-
tion with high morbidity.
The interpretation of the results of this study is limited by the 
retrospective design and the relatively small number of patients 
per subgroup. However, to our knowledge, this is the first study 
addressing the value of FDG-PET/CT scans specifically in criti-
cally ill neurological patients.
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